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Abstract 
The treatment of bacterial infections has been successfully achieved when antibiotics 
were first introduced. A short while after the introduction of antibiotics, bacterial strains 
became resistant to antibiotic treatment, and bacterial infections were potentially fatal 
once again. This challenge has led to various pursuits of antibiotic alternative treatment. 
The antibacterial effect of colloidal silver (18 and 20 ppm) was investigated on 
Staphylococcus aureus and Streptococcus pyogenes in vitro using the microdilution 
method. Agar disc diffusion method was used as trial run. Zones of inhibition were 
measured and recorded in the agar disc diffusion method to indicate bacterial inhibition. 
The Iodonitrotetrazolium chloride dye was added to the 96 well microplate in the 
microdilution method and colour changes were visually observed. An unchanged clear 
colour indicated bacterial inhibition. Noticeable colour changes (from a clear colour to 
purple) indicated bacterial growth. The results from both experimental methods showed 
that both 18 and 20 ppm colloidal silver had an inhibitory effect against Streptococcus 
pyogenes, but not against Staphylococcus aureus. This warrants further extensive 
research on the effect of colloidal silver as an antimicrobial.  
Introduction 
Streptococcus pyogenes (S. pyogenes) and Staphylococcus aureus (S. aureus) are both 
Gram-positive bacteria which are responsible for various communicable infections, most of 
which can be fatal if left untreated. The infections caused by S. pyogenes include 
pharyngitis, streptococcal tonsillitis, impetigo, cellulitis and pyoderma (Ahmad et al., 2014). 
Streptococcal infections have been linked with increased rates of mortality in poorly 
developed countries, while it has declined greatly in well-developed countries (Carapetis 
et al., 2005). Towards the end of the 20th century, there has been a decline in the 
incidence and severity of streptococcal infections due to the use of antibiotics; however, in 
the past 15years, the incidence of streptococcal infections peaked again in a more severe 
manner due to the increase of antibiotic resistant bacterial strains and challenges 
eradicating the strains thereof (Luca-Harari et al, 2009). Infection by S. aureus is prevalent 
in individuals with compromised immune systems, causing scalded skin syndrome, 
abscesses, nosocomial pneumonia, meningitis, osteomyelitis and toxic shock syndrome 
(Stevens et al., 2002). According to Schaumburg et al. (2014) about 3.28 cases per 1 000 
hospital admissions in South Africa are due to S. aureus infection annually. In 
Mozambique, 178 cases per 100 000 hospital admissions are due to infection by S. 
aureus compared to the United States of America, which has about 2.3 cases per 100 000 
hospital admissions yearly. 
                  
The introduction of antibiotics has successfully and effectively combated many bacterial 
infections; however more and more bacterial strains are becoming resistant to antibiotic 
drug treatment (WHO, 2015). Drug resistant bacterial strains are influenced by various 
factors, including but not limited to genetic mutation, bacterial strains acquiring genes 
conferring drug resistance (Martínez, 2012), easily accessible non-prescription antibiotics, 
poor compliance to antibiotics, and inadequate access to proper treatment due to the 
unavailability of antibiotics   (WHO, 2015; Tangcharoensathien et al, 2018) .  
Due to the many challenges with antibiotic use, most people are seeking complementary 
and alternative treatment for bacterial infections (Wolsko et al., 2002). Colloidal silver is 
widely known as an alternative antimicrobial. It is known to have no interactions with other 
forms of treatments, therefore can be taken safely with other drugs (Iroha et al., 2007). 
Although considered safe, the prolonged use of colloidal silver results in a permanent blue 
appearance, known as argyria (Owen, 2013).  Many claims have been made and research 
studies have been conducted on colloidal silver as a potent antimicrobial, no research is 
known to have been done specifically on colloidal silver 18 and 20 ppm against S. aureus 
and S. pyogenes.  
 
The microdilution minimum inhibitory concentration (MIC) method was used to investigate 
the anti-bacterial effect of colloidal silver on S. pyogenes and S. aureus. The MIC is a 
standardized, accurate, easy and inexpensive experiment to carry out. MIC is the 
concentration at which visible bacterial growth is prevented under certain growth 




Materials and method 
Ethical considerations 
The research study was carried out after permission was granted by The Faculty 
Academic Ethics Committee. The experiments were done at the University of 
Johannesburg’s Water and Health Research Centre, Doornfontein Campus, under 
supervision of a qualified laboratory technician and with permission granted. 
 
Laboratory protection and safety 
Upon entering the laboratory, hygiene measures, like washing hands, cleaning working 
area surfaces and sterilizing instruments with ethanol, were taken.  
A laboratory coat, hand gloves as well body covering clothing and shoes were worn during 
laboratory experiments for protection of self from accidental spills.  
Instrumentation and material used were handled away from self and laboratory technician 
for protection. Inflammable substances were used with caution.  
All laboratory instruments used during experiments were washed at the end of each 
experiment. Disposables were discarded in relevant bins provided by the laboratory 
technician after use. 
 
Materials  
Reference strains of Streptococcus pyogenes (ATCC 12384) and Staphylococcus aureus 
(ATCC Baa-1026) were purchased in a lyophilised form. The strains were stored at 4-5°C 
and reconstituted in sterile saline water as required. Table 1 below summarizes the media, 
buffers, chemicals and consumables used in the study.  
 
Cefepime hydrochloride monohydrate was used as positive control against both the S. 
aureus and S. pyogenes strains during the experiments. Two different concentrations of 
colloidal silver (18 ppm and 20 ppm) were used as test compound. The 18 ppm colloidal 
silver (Silver lab) contains ionic colloidal silver in deionized purified water. The 20 ppm 
colloidal silver (BIO-SIL) contains ISO 3696 distilled water and fine silver. The treatment 







Table 1 Summary of media, reagents and chemicals used for the experimental work. 
Description Catalogue number Supplier 
Unsensitized tubes 69285 Biomerieux 
Saline solution V1204 Biomerieux 
Mueller Hinton agar CM0337B Laboratory Specialities (PTY) LTD T/A Thermo Fisher Scientific (Oxoid) 
Petri dish 90mm 1C097 Clinical Science Diagnostics 
96-well microplate with lid 734-2097 Monitoring & Control Laboratories (Nunc) 
Swabs PS cotton in PP 
tube sterile 300261 Merck Chemicals (Deltalab) 
P-Iodonitrotetrazolium violet I8377 Sigma Aldrich 
Neomycin sulfate hydrate J61499.14 Monitoring & Control Laboratories 
Cefepime hydrochloride 
monohydrate J66237.03 Monitoring & Control Laboratories 
Cartridges blank CT0998B Laboratory Specialities (PTY) LTD T/A Thermo Fisher Scientific (Oxoid) 
Inoculating loops, 10ul 612-9354 Monitoring & Control Laboratories (VWR) 
Agarose BIO-41025 Celtic Molecular Diagnostics (Bioline) 
Tris-HCl T3253 Sigma Aldrich 





Aseptic techniques were adhered too, to ensure that no contamination takes place, thus 
ensuring reliability of results.  
  
Growth and maintenance of bacteria 
The stock culture arrived freeze dried in a vial/container and needed to be hydrated before 
use. The unopened vial was taken out of the storage and allowed to equilibrate to room 
temperature. The vial was opened and sterile forceps used to remove one pellet of 
bacteria without removing the desiccant. Immediately, the vial was recapped and returned 
to the storage of 4-5°C. The pellet of bacteria was inoculated into a sterile flask containing 
100 ml saline solution. A sterile swab was used to crush the pellet and it was heavily 
saturated in the hydrated suspension.  
 
The saturated swab was used to inoculate the Mueller-Hinton agar culture plate, with the 
swab streaked over one-third of the plate. Inoculations were placed in an incubator for 24 
hours at 35°C.  
 
The streak plate method was used to subculture S. pyogenes and S. aureus onto Mueller-
Hinton agar plates. Fresh cultures were prepared for each experiment.  
 
A sterile cotton swab was used to transfer bacteria onto agar plates for subculturing. 
Bacteria were spread onto plates in a zigzag pattern using sterile plastic inoculating loops. 
A new loop was used between each step, and the used swabs and loops were discarded 
for safe disposal. The agar plates were then incubated for 24 hours at 35°C and used to 
prepare the bacterial suspension required for the experiments. 
 
Preparation of media 
Mueller-Hinton broth was used as media in the study. It consists of beef infusion from 
casein acid hydrolysate and starch. To prepare the media, 21 g of the powder was 
suspended in 1 000 ml distilled water. This suspension was heated to boil to dissolve the 
medium. For sterilization, the solution was autoclaved at 121°C for 15 minutes. The media 
was cooled to about 50°C and poured into sterile plastic petri dishes. After solidification of 
the agar, the plates were stored at 4°C. 
 
Preparation of the Iodonitrotetrazolium chloride solution 
A 0.4 mg/ml working solution of the Iodonitrotetrazolium chloride (INT) was prepared using 
sterile water and stored at 4°C until needed. The solution was used in the sections below. 
 
Disc diffusion method 
This method was used to as trial run. Bacterial strains were prepared and subcultured 
grown as described above, and used to create the bacterial lawns on the Mueller-Hinton 
agar plates. The bacterial lawns were created by transferring colonies from the agar plate 
with subcultured bacteria into the test tube containing saline. The bacterial suspension 
was adjusted with saline to reach a solution correlating to a 0.5 McFarland standard. A 
sterile cotton swab was immersed in this suspension and the total area of the agar plate 
covered with the bacterial suspension.  
 
Sterile discs were placed onto the media with sterile forceps according to pre-designed 
grid to allow the placement of multiple discs on each plate. Following this, 20 µl of each 
test solution, blank control (sterile water added), solution control (saline solution) and 
positive control (Cefepime) was added onto the discs.   
 
These plates were covered and  incubated for 24 hours at 35°C. Following incubation, the 
plates were taken out and placed on a sterile working surface. To assist in the 
visualization of the bacterial-inhibition, an agarose overlay containing INT (final electron 
acceptor) was added onto the plates. The INT overlay was prepared by mixing it with 1% 
(w/v) agarose solution (prepared in Tris-Acetic-EDTA buffer, pH 8.3), to a final INT 
concentration 0.2 mg/ml. The plates were incubated at 37°C until a bright pink or dark pink 
colour developed, indicating bacterial growth, i.e. no bacterial inhibition.  
 
Microdilution method 
The microdilution method was used as an antibiotic susceptibility test to determine the 
sensitivity of the bacteria (S. aureus and S. pyogenes) against colloidal silver. The 
bacterial suspension used for this method, corresponding to a 0.5 McFarland standard, 
was prepared as described above. The 96 well plates were divided into two halves to 
accommodate the two bacteria used.  
 
The first half (1-6) was used for S. aureus and the second half (7-12) was for S. pyogenes. 
 
All wells were filled with 100 µl Mueller Hinton broth. Fifty microliters of either test 
compound, cefepime (positive control), media (media control to test sterility), water 
(negative or growth control) were added to the first well in each row. The compounds were 
serially diluted in the next well by transferring 50 µl   from the first well, mixing properly, 
and by transferring 50 µl into the next well.  This was continued to the last well (6th well) 
and the last 50 µl removed was safely discarded. Lastly, 50 µl of the required bacterial 
suspension was added to each of the wells, excluding the media control wells that 
received 50 µl saline solution. The plates were then closed and incubated for 24 hours at 
35°C.  
 
Following incubation, 100 µl of the INT solution was added to each well and incubated for 
30 minutes at 35°C. The development of a bright pink of dark pink colour indicated 
bacterial growth, i.e. no bacterial inhibition. 
 
Results 
Agar disc diffusion method 
The agar disc diffusion method, also known as the Kirby Bauer disc diffusion method, was 
used to test whether or not the two compounds could inhibit bacterial growth for both S. 
aureus and S. pyogenes. The results were visually inspected, and zones of inhibition were 
measured. Examples of typical results obtained for both bacteria is shown in Figures 4.1.  
 
(i)                                                             (ii) 
Figure 4.1 Agar plates showing typical results obtained for the colloidal silver solutions 
against S. pyogenes (i) and S. aureus (ii), as well as bacterial lawns using 
the agar disc diffusion method.  
 
The quarters in figure 4.1 represent the 18 ppm colloidal silver solution (A), 20 ppm 
colloidal silver solution (B), Cefepime control (C) and distilled water control (D). By visual 
inspection of the result images in figure 4.1, both concentrations of colloidal silver inhibited 
the bacterial growth of S. pyogenes, but not that of S. aureus; Cefepime control antibiotic 
exhibited an inhibitory effect on both bacteria used; and distilled water control showed no 
effect against both S. pyogenes and S. aureus.   





 Microdilution method  
This method was used for confirmatory purposes after results have been obtained with 
agar disc diffusion method. Figure 4.2 below shows the typical 96 well plate layout used to 
test the compounds using the microdilution method. The dilutions, stains and well 
composition is shown in the figure. The 18 ppm colloidal silver solution is shown as C1 
and 20 ppm colloidal silver solution as C2.  
 
Wells that changed colour from clear to purple after the addition of the INP showed growth 
and thus no inhibition of bacterial growth by treatment compounds. The wells with an 





Figure 2 The typical microdilution method results of 96 well plate layout used to test 
the compounds using the microdilution method.  
 
The microdilution method was used to determine the Minimum Inhibitory Concentration 
(MIC) for the compounds against the two bacterial strains.  
The results obtained with the microdilution method confirmed that both the 18 ppm and 20 
ppm colloidal silver solution had no effect on the S. aureus strain as the colour turned from 
clear to purple; however, the colloidal silver 20ppm demonstrated an inhibitory effect of S. 
pyogenes as the colour remained.  
 
Discussion  
The results demonstrated that S. pyogenes growth was inhibited by both the 18 ppm and 
20 ppm colloidal silver solutions tested and which was confirmed by agar disc diffusion 
method and microdilution method. None of the colloidal silver solutions had any inhibitory 
effect on the S. aureus strain used. This attributed to various factors, including antibiotic 
resistance, the concentration of colloidal silver used and the method of choice.  
S. aureus is more virulent than S. pyogenes (Acharya, 2015) and therefore prone to be 
resistance to treatment. It may have either adapted to the experimental environment and 
developed resistance or genetic mutation of the strain could have occurred, resulting in 
resistance.  
 
Gutierrez et al. (2013) mentioned that Subinhibitory concentrations of antimicrobials may 
provoke cellular changes in bacteria. Both 18 and 20 ppm colloidal silver concentrations 
might have been too low that they caused S. aureus to change its structure to adapt to the 
environment and develop resistance to colloidal silver. Doss et al. (1993) further confirms 
that low concentrations of antibiotics also induce genetic transformation as well as the 
expression of virulence genes, thus exhibiting resistance to antimicrobials. The study 
published by Concepcion et al. (2007) showed that with their colloidal silver mixtures, only 
higher concentrations of colloidal silver (30 ppm) were effective against S. aureus, 
suggesting that the two compounds tested may have had too low a concentration of the 
active compound.  Colloidal silver 18 ppm and 20 ppm were chosen based on the 
availability by manufacturing companies (Silverlab and Biosil), and on the fact that no 
studies are known to have been done using these concentrations.   
 
Concepcion et al (2007) and his team evaluated the antimicrobial activity of colloidal silver 
(10 ppm, 20 ppm, and 30 ppm) compared with ophthalmic antibiotics including trobamycin, 
lomefloxin, ampicillin, and moxifloxacin. These were tested against Escherichia coli, S. 
aureus, Staphylococcus epidermis, and Bacillus subtilis using the antibacterial-activity 
testing (ABAT) and Kirby Bauer methods. The Kirby Bauer disc diffusion method (agar 
disc diffusion method) demonstrated that the bacteria tested was sensitive to 30 ppm 
colloidal silver, with the zone of inhibition more pronounced than that of trobamycin and 
ampicillin against S. aureus. No zone of inhibition was noted for all three concentrations of 




The results demonstrated that S. pyogenes growth was inhibited by both the 18 ppm and 
20 ppm colloidal silver solutions tested and which was confirmed by agar disc diffusion 
method and microdilution method. None of the colloidal silver solutions had any inhibitory 
effect on the S. aureus strain used. As discussed in sections above, either the S.aureus 
strain could have developed resistance to the colloidal silver solutions, or the colloidal 
silver solution may have had too low concentration of the active compound to be effective 
against this strain.   
 
In conclusion, colloidal silver (18 ppm and 20 ppm) have an anti-bacterial effect on S. 
pyogenes, but not on S. aureus. This research has added to the developing volume of 
information to better understand the antibacterial effect and efficiency of colloidal silver 
mixtures. Further research needs to be conducted to determine whether or not the 
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